Recognition of Amino Acid Motifs, Rather Than Specific Proteins, by Human Plasma Cell-Derived Monoclonal Antibodies to Posttranslationally Modified Proteins in Rheumatoid Arthritis.


Journal

Arthritis & rheumatology (Hoboken, N.J.)
ISSN: 2326-5205
Titre abrégé: Arthritis Rheumatol
Pays: United States
ID NLM: 101623795

Informations de publication

Date de publication:
02 2019
Historique:
received: 22 12 2017
accepted: 23 08 2018
pubmed: 29 8 2018
medline: 5 11 2019
entrez: 29 8 2018
Statut: ppublish

Résumé

Antibodies against posttranslationally modified proteins are a hallmark of rheumatoid arthritis (RA), but the emergence and pathogenicity of these autoantibodies are still incompletely understood. The aim of this study was to analyze the antigen specificities and mutation patterns of monoclonal antibodies (mAb) derived from RA synovial plasma cells and address the question of antigen cross-reactivity. IgG-secreting cells were isolated from RA synovial fluid, and the variable regions of the immunoglobulins were sequenced (n = 182) and expressed in full-length mAb (n = 93) and also as germline-reverted versions. The patterns of reactivity with 53,019 citrullinated peptides and 49,211 carbamylated peptides and the potential of the mAb to promote osteoclastogenesis were investigated. Four unrelated anti-citrullinated protein autoantibodies (ACPAs), of which one was clonally expanded, were identified and found to be highly somatically mutated in the synovial fluid of a patient with RA. The ACPAs recognized >3,000 unique peptides modified by either citrullination or carbamylation. This highly multireactive autoantibody feature was replicated for Ig sequences derived from B cells from the peripheral blood of other RA patients. The plasma cell-derived mAb were found to target distinct amino acid motifs and partially overlapping protein targets. They also conveyed different effector functions as revealed in an osteoclast activation assay. These findings suggest that the high level of cross-reactivity among RA autoreactive B cells is the result of different antigen encounters, possibly at different sites and at different time points. This is consistent with the notion that RA is initiated in one context, such as in the mucosal organs, and thereafter targets other sites, such as the joints.

Identifiants

pubmed: 30152202
doi: 10.1002/art.40699
pmc: PMC6563427
doi:

Substances chimiques

Anti-Citrullinated Protein Antibodies 0
Antibodies, Monoclonal 0
Autoantibodies 0
Autoantigens 0
Immunoglobulin G 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

196-209

Subventions

Organisme : Knut and Alice Wallenberg Foundation
Pays : International
Organisme : European Research Council
ID : 250167
Pays : International
Organisme : BTCure program
ID : 115142-2
Pays : International
Organisme : Swedish Association Against Rheumatism
Pays : International
Organisme : King Gustaf V's 80-year Foundation
Pays : International
Organisme : Swedish Medical Research Council
Pays : International

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

© 2018 The Authors. Arthritis & Rheumatology published by Wiley Periodicals, Inc. on behalf of American College of Rheumatology.

Références

J Rheumatol. 2003 Aug;30(8):1696-711
pubmed: 12913924
J Immunol. 1999 Jan 1;162(1):585-94
pubmed: 9886436
Ann Rheum Dis. 2016 Apr;75(4):721-9
pubmed: 26612338
Sci Transl Med. 2013 Mar 27;5(178):178ra40
pubmed: 23536012
Arthritis Rheumatol. 2014 Jan;66(1):31-9
pubmed: 24449573
Arthritis Rheumatol. 2014 Jul;66(7):1712-22
pubmed: 24665079
Ann Rheum Dis. 2016 Oct;75(10):1866-75
pubmed: 26659717
Ann Rheum Dis. 2016 Oct;75(10):1876-83
pubmed: 26659718
Nat Med. 2012 Feb 26;18(3):441-5
pubmed: 22366952
Arthritis Rheumatol. 2014 Oct;66(10):2706-15
pubmed: 24965753
J Exp Med. 2013 Mar 11;210(3):445-55
pubmed: 23440041
Ann Rheum Dis. 2016 Apr;75(4):730-8
pubmed: 26613766
Ann Rheum Dis. 2016 Sep;75(9):1722-7
pubmed: 26530319
MAbs. 2014 Jan-Feb;6(1):143-59
pubmed: 24423622
Nat Genet. 2012 Dec;44(12):1336-40
pubmed: 23143596
Mol Cell Proteomics. 2014 Jun;13(6):1585-97
pubmed: 24705123
Proc Natl Acad Sci U S A. 2011 Oct 18;108(42):17372-7
pubmed: 21987802
Eur J Immunol. 2016 Dec;46(12):2812-2821
pubmed: 27645315
Arthritis Rheum. 2010 Jan;62(1):44-52
pubmed: 20039432
Ann Rheum Dis. 2016 Jun;75(6):1099-107
pubmed: 26160441
Rheumatology (Oxford). 2007 Feb;46(2):342-9
pubmed: 16899498
Nat Immunol. 2015 Jul;16(7):755-65
pubmed: 26006014
Ann Rheum Dis. 2011 Feb;70(2):259-65
pubmed: 21156761
J Exp Med. 2005 Mar 7;201(5):703-11
pubmed: 15738055
J Clin Invest. 2006 Dec;116(12):3183-94
pubmed: 17143328
Immunogenetics. 2002 Jun;54(3):141-57
pubmed: 12073143
J Clin Invest. 2012 May;122(5):1791-802
pubmed: 22505457
Arthritis Res Ther. 2005;7(5):R949-58
pubmed: 16207336
Clin Proteomics. 2014 Jan 06;11(1):1
pubmed: 24393543
Front Immunol. 2016 Nov 14;7:494
pubmed: 27895642
Arthritis Rheum. 2003 Oct;48(10):2741-9
pubmed: 14558078
Eur J Immunol. 2005 May;35(5):1643-52
pubmed: 15832289
Arthritis Rheumatol. 2015 May;67(8):2020-31
pubmed: 25892475
Arthritis Res Ther. 2004;6(2):R142-50
pubmed: 15059278
Cell. 2016 Jul 28;166(3):582-595
pubmed: 27426947
Arthritis Res Ther. 2014;16(2):R90
pubmed: 25167216
Rheumatology (Oxford). 2013 Apr;52(4):631-5
pubmed: 23264551
J Immunol. 2001 Mar 15;166(6):4177-84
pubmed: 11238669
Science. 2011 Sep 16;333(6049):1633-7
pubmed: 21764753
Proc Natl Acad Sci U S A. 2013 May 7;110(19):7832-7
pubmed: 23620516
Ann Rheum Dis. 2016 Mar;75(3):578-85
pubmed: 25587188
Arthritis Rheumatol. 2018 Dec;70(12):1933-1945
pubmed: 29927106
Eur J Immunol. 2018 Jun;48(6):1030-1045
pubmed: 29512823
Matrix Biol. 2016 Jan;49:10-24
pubmed: 26163349
Arthritis Rheumatol. 2016 Mar;68(3):614-26
pubmed: 26474325
Science. 2010 Aug 13;329(5993):811-7
pubmed: 20616231
Arthritis Res Ther. 2012 Oct 01;14(5):R201
pubmed: 23025688
Arthritis Rheum. 2010 Sep;62(9):2569-81
pubmed: 20872595
Arthritis Res Ther. 2005;7(6):R1421-9
pubmed: 16277695
J Clin Invest. 1998 Jan 1;101(1):273-81
pubmed: 9421490

Auteurs

Johanna Steen (J)

Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.

Björn Forsström (B)

KTH Royal Institute of Technology, Stockholm, Sweden.

Peter Sahlström (P)

Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, and Charité Univeristätsmedizin, Berlin, Germany.

Victoria Odowd (V)

UCB Pharma, Slough, UK.

Lena Israelsson (L)

Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.

Akilan Krishnamurthy (A)

Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.

Sara Badreh (S)

Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.

Linda Mathsson Alm (L)

Thermo Fisher Scientific and Uppsala University, Uppsala, Sweden.

Joanne Compson (J)

UCB Pharma, Slough, UK.

Daniel Ramsköld (D)

Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.

Welcome Ndlovu (W)

UCB Pharma, Slough, UK.

Stephen Rapecki (S)

UCB Pharma, Slough, UK.

Monika Hansson (M)

Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.

Philip J Titcombe (PJ)

Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, and University of Minnesota Medical School, Minneapolis.

Holger Bang (H)

Orgentec Diagnostika, Mainz, Germany.

Daniel L Mueller (DL)

University of Minnesota Medical School, Minneapolis.

Anca I Catrina (AI)

Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.

Caroline Grönwall (C)

Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.

Karl Skriner (K)

Charité Univeristätsmedizin, Berlin, Germany.

Peter Nilsson (P)

KTH Royal Institute of Technology, Stockholm, Sweden.

Daniel Lightwood (D)

UCB Pharma, Slough, UK.

Lars Klareskog (L)

Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.

Vivianne Malmström (V)

Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH